Yichuan Fan1, Xingzhi Zhao1, Xiaodong Li1, Nan Li1, Xinhua Hu2. 1. Department of Vascular and Thyroid Surgery, The First Affiliated Hospital, China Medical University, Shenyang 110001, China. 2. Department of Vascular and Thyroid Surgery, The First Affiliated Hospital, China Medical University, Shenyang 110001, China. Electronic address: xinhuahu@126.com.
Abstract
BACKGROUND: The prognostic value of cardiac troponin elevation in atrial fibrillation (AF) is unclear. OBJECTIVE: To investigate the association of cardiac troponin elevation with adverse outcomes in AF by conducting a meta-analysis. METHODS: We systematically searched the PubMed and Embase databases until April 2017 for studies assessing the association of cardiac troponin-T (cTnT) or troponin-I (cTnI) elevation with adverse outcomes in AF. The outcome measures were all-cause mortality and major adverse cardiac events (MACEs: death, stroke, myocardial infarction, pulmonary embolism, major bleeding, or revascularization). RESULTS: Six studies involving 22,697 AF patients were identified. Meta-analysis showed that AF with elevated cardiac troponin was independently associated with increased risk of all-cause mortality (HR 2.04; 95% CI 1.56-2.67) and MACEs (HR 1.93; 95% CI 1.61-2.30). Furthermore, the prognostic value of cardiac troponin elevation was consistently found irrespective of method determination, type of troponin measured, sample size, and study quality subgroup. CONCLUSIONS: AF with cardiac troponin elevation was independently associated with increased risk of all-cause mortality and MACEs. Therefore, determination of troponin should be considered for risk stratification in AF.
BACKGROUND: The prognostic value of cardiac troponin elevation in atrial fibrillation (AF) is unclear. OBJECTIVE: To investigate the association of cardiac troponin elevation with adverse outcomes in AF by conducting a meta-analysis. METHODS: We systematically searched the PubMed and Embase databases until April 2017 for studies assessing the association of cardiac troponin-T (cTnT) or troponin-I (cTnI) elevation with adverse outcomes in AF. The outcome measures were all-cause mortality and major adverse cardiac events (MACEs: death, stroke, myocardial infarction, pulmonary embolism, major bleeding, or revascularization). RESULTS: Six studies involving 22,697 AFpatients were identified. Meta-analysis showed that AF with elevated cardiac troponin was independently associated with increased risk of all-cause mortality (HR 2.04; 95% CI 1.56-2.67) and MACEs (HR 1.93; 95% CI 1.61-2.30). Furthermore, the prognostic value of cardiac troponin elevation was consistently found irrespective of method determination, type of troponin measured, sample size, and study quality subgroup. CONCLUSIONS:AF with cardiac troponin elevation was independently associated with increased risk of all-cause mortality and MACEs. Therefore, determination of troponin should be considered for risk stratification in AF.
Authors: Yunju Yang; Traci M Bartz; Michael R Brown; Xiuqing Guo; Nuno R Zilhão; Stella Trompet; Stefan Weiss; Jie Yao; Jennifer A Brody; Christopher R Defilippi; Ron C Hoogeveen; Henry J Lin; Vilmundur Gudnason; Christie M Ballantyne; Marcus Dörr; J Wouter Jukema; Astrid Petersmann; Bruce M Psaty; Jerome I Rotter; Eric Boerwinkle; Myriam Fornage; Goo Jun; Bing Yu Journal: Circ Genom Precis Med Date: 2021-11-04
Authors: Alejandro O Luquetti; Dayse Elisabeth Campos de Oliveira; Suelene Brito do Nascimento Tavares; Enio Chaves de Oliveira Journal: Am J Trop Med Hyg Date: 2022-03-28 Impact factor: 3.707
Authors: L M G Meems; V Artola Arita; M Velt; E A M P Dudink; H J G M Crijns; I C Van Gelder; M Rienstra Journal: Int J Cardiol Heart Vasc Date: 2022-03-08